It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Turning promising leads into clinical candidates with speed, precision, and scientific expertise. We generate high-quality data and deliver real patient impact.
Every lead optimization program at Sygnature Discovery is built around cross-disciplinary collaboration.
Our integrated teams tailor molecular structures to enhance novelty, potency and safety, while optimizing ADMET properties for the right exposure, duration and target engagement.
Working in a multidisciplinary and highly collaborative environment maximizes efficiency and drives understanding and optimization of Structure-Activity Relationships (SAR). We build strong partnerships with our customers, offering strategic, proactive solutions tailored to each program’s needs.
Using advanced informatics systems, we present and analyse data transparently, enabling rapid prioritization of synthetic targets and assay cascades. As candidate selection approaches, our experienced DMPK scientists establish in vitro to in vivo correlations and predict human dosing, helping you make informed decisions with clarity and speed.
Key Benefits
At Sygnature Discovery, we are ideally equipped to transform your early lead into a clinical- quality molecule in a cost-effective and efficient manner. Drawing upon key investments in people and infrastructure, our teams deliver:
Speed & Efficiency
Our co-located project teams streamline DMTA cycle and enable fast, informed decision-making to keep your project moving.
Fast Path to Advanced Studies
Internal route development, scale-up, and formulation capabilities allow rapid delivery of large-scale API for IND-enabling studies and smooth transfer to GMP manufacturing.
High-Quality Data, Quickly
We generate robust data rapidly and use advanced informatics to identify the most promising molecule, giving you confidence in candidate selection.
Our Expertise in Lead Optimization Techniques
We know what it takes to evolve a pharmaceutical tool into a compound ready for human trials. Our drug discovery scientists balance potency, selectivity, DMPK, safety, and target engagement to deliver candidate with clinical potential.
In parallel, our in vivo and biomarker experts identify the most relevant models and biomarkers for patient selection and target engagement. Our Therapeutic Area specialists bring insight into the clinical landscape beyond preclinical development positioning your project for a successful IND application and clinical entry. Because for us, real patient benefit is the ultimate measure of success.
Why Choose Sygnature Discovery for Lead Optimization Support ?
Our contributions to complex hit-to-lead projects are reflected in over 230 patents, numerous publications, and conference presentations. We’re named investors on patents for more than 60 preclinical and 35 clinical candidates, and our data has supported many successful IND applications.
With a proven track record, we help de-risk your path to the clinic and accelerate progress toward pivotal IND-enabling studies. Let’s turn your ideas into clinical realities.
Case Studies
Trusted by customers worldwide
Our customers tell us that we act as an extension of their team and provide high quality expertise at every stage of the drug discovery process. Whether we’re supporting you through the entire process, or just a part of it, our goal isn’t simply to move you to the next stage it’s to lay the foundations for a successfully marketed drug.
From Lead to Pre-Candidate Nomination in 18 Months
Progressing from lead to pre candidate nomination in less than half the industry standard timeline, this program shows how connected scientific teams and real time insight can accelerate complex discovery.
Many intriguing drug discovery programmes begin life at start-up biotech companies. Yet at the outset, these new organisations rarely have the resources or laboratory set-up immediately available to turn their ground-breaking ideas into a new medicine.
Rapid creation of ideas using generative AI (GenAI) with Iktos Makya
Leading generative artificial intelligence (GenAI) algorithms for de novo design are being used routinely within our medicinal chemistry programmes to enable rapid idea generation to address project objectives.
Fragment-based hit discovery for the epigenetic target, BRD3
Fragment-based drug discovery allows a wide section of chemical space to be interrogated with a relatively small but diverse library of small molecules.
Accelerating a best in class DHX9 inhibitor ahead of industry timelines.
See how STORM Therapeutics and Sygnature Discovery moved from lead to pre candidate nomination in
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
Discover CHARMED, Sygnature’s innovative PROTAC platform, showcasing rapid degrader identification demonstrated with SHP2 as a model oncology target. Explore our advancements in protein degradation.
A new treatment for G4-targeted solid tumors including pancreatic cancer has been administered…
News
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
DMPK
Integrated DMPK solutions combining advanced assays, modeling, and bioanalysis delivering predictive insights that reduce risk and guide candidate selection.
Validated in vivo models deliver clinically relevant data across therapeutic areas, accelerating confident decisions and reducing risk in drug development.
Delivering validated, high-quality hits through integrated technologies, strategic insight, and expert collaboration to advance your program with confidence.
